

- primary thyroid lymphoma: a long-term study involving 24,553 patients with Hashimoto's disease. *Br J Haematol.* 2011
10. Okuda C, Kim YH, Takeuchi K, Togashi Y, Masago K, Sakamori Y, Mio T, Mishima M. Successful treatment with pemetrexed in a patient with mucinous bronchioloalveolar carcinoma: long-term response duration with mild toxicity. *J Thorac Oncol.* 641-642, 2011
 11. Takeuchi K, Soda M, Togashi Y, Ota Y, Sekiguchi Y, Hatano S, Asaka R, Noguchi M, Mano H. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. *Haematologica.* 2011
 12. Nakajima T, Kimura H, Takeuchi K, Soda M, Mano H, Yasufuku K, Iizasa T. Treatment of Lung Cancer with an ALK Inhibitor After EML4-ALK Fusion Gene Detection Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. *J Thorac Oncol.* 5:2041-2043, 2010
 13. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, Ishikawa Y, Kimura H, Mitsudomi T, Tanio Y, Mano H. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med.* 363:1734-1739. 2010
 14. Nishimori H, Takahashi S, Kiura K, Ennishi D, Kobayashi T, Sano K, Shinozaki E, Yokoyama M, Mishima Y, Terui Y, Chin K, Mizunuma N, Ito Y, Nishimura S, Takeuchi K, Ishikawa Y, Oguchi M, Tanimoto M, Hatake K. Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan. *Acta Med Okayama.* 64:285-291, 2010
 15. Jokoji R, Yamasaki T, Minami S, Komuta K, Sakamaki Y, Takeuchi K, Tsujimoto M. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. *J Clin Pathol.* 63:1066-1070, 2010
 16. Sakairi Y, Nakajima T, Yasufuku K, Ikebe D, Kageyama H, Soda M, Takeuchi K, Itami M, Iizasa T, Yoshino I, Mano H, Kimura H. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. *Clin Cancer Res.* 16:4938-4945, 2010
 17. Takeuchi K, Yokoyama M, Ishizawa S, Terui Y, Nomura K, Marutsuka K, Nunomura M, Fukushima N, Yagyu T, Nakamine H, Akiyama F, Hoshi K, Matsue K, Hatake K, Oshimi K. Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. *Blood* 116:5631-5637, 2010
 18. Kodaira M, Takahashi S, Takeuchi K, Yuasa T, Saotome T, Yonese J, Fukui I, Hatake K. Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma. *Ann Oncol.* 21:1563-1565, 2010
 19. Asai H, Yokoyama M, Terui Y, Ennishi D, Takeuchi K, Hatake K. Is statin use really associated with efficacy of rituximab? *J Clin Oncol.* 28:e424-425; author reply e427-428, 2010
 20. Hoshi R, Furuta N, Horai T, Takeuchi K, Ishikawa Y, Satoh Y. Implications for differential diagnosis of lung cancer-associated lymphadenopathy in lymphoepithelioid cell lymphoma (Lennert's lymphoma) arising simultaneously with lung cancer: a case report. *Acta Cytol.* 54:197-201, 2010
 21. Ichinohasama R, Oji Y, Yokoyama H, Takeuchi K, Fujiwara T, Ishizawa K, Taniguchi O, Tsuboi A, Oka Y, Sugiyama H. Sensitive

- immunohistochemical detection of WT1 protein in tumors with anti-WT1 antibody against WT1 235 peptide. *Cancer Sci.* 101:1089-1092, 2010
22. Tsuji H, Tamura M, Yokoyama M, Takeuchi K, Mimura T. Ocular involvement by Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a new disease entity in the World Health Organization classification. *Arch Ophthalmol.* 128:258-259, 2010
 23. Hiramatsu M, Ninomiya H, Inamura K, Nomura K, Takeuchi K, Satoh Y, Okumura S, Nakagawa K, Yamori T, Matsuura M, Morikawa T, Ishikawa Y. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. *Lung Cancer.* 70:94-102, 2010
 24. Mano H, Takeuchi K. EML4-ALK fusion in lung. *Am J Pathol.* 176:1552-1553; author reply 1553-1554, 2010
 25. Watanabe R, Tomita N, Takeuchi K, Sakata S, Tateishi U, Tanaka M, Fujita H, Inayama Y, Ishigatsubo Y. SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. *Leuk Lymphoma.* 51:279-283, 2010
 26. Kodaira M, Takahashi S, Yamada S, Ueda K, Mishima Y, Takeuchi K, Yamamoto N, Ishikawa Y, Yokoyama M, Saotome T, Terui Y, Hatake K. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy. *Ann Oncol.* 21:1163-1167, 2010
 27. Ennishi D, Asai H, Maeda Y, Shinagawa K, Ikeda K, Yokoyama M, Terui Y, Takeuchi K, Yoshino T, Matsuo K, Hatake K, Tanimoto M. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. *Ann Oncol.* 21:1217-1221, 2010
 28. Hyo R, Tomita N, Takeuchi K, Aoshima T, Fujita A, Kuwabara H, Hashimoto C, Takemura S, Taguchi J, Sakai R, Fujita H, Fujisawa S, Ogawa K, Motomura S, Suzuki R, Ishigatsubo Y. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. *Hematol Oncol.* 28(1):27-32, 2010
 29. Ennishi D, Yokoyama M, Terui Y, Asai H, Sakajiri S, Mishima Y, Takahashi S, Komatsu H, Ikeda K, Takeuchi K, Tanimoto M, Hatake K. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. *Ann Oncol.* 20:26-533, 2010
 30. Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, Miyamoto K, Kikuchi A, Hyo R, Yakushijin Y, Masaki Y, Fujii S, Hayashi T, Ishigatsubo Y, Miura I. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. *Haematologica.* 94(7):935-43, 2009
 31. Tomita N, Takeuchi K, Hyo R, Hashimoto C, Takemura S, Taguchi J, Fujita H, Fujisawa S, Ogawa K, Motomura S, Ishigatsubo Y. Diffuse Large B Cell Lymphoma without Immunoglobulin Light Chain Restriction by Flow Cytometry. *Acta Haematol.* 121:196-201, 2009
 32. Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Kuniyoshi R, Taniyama A, Yokoyama M, Sakajiri S, Takeuchi K, Watanabe C, Takahashi S, Ito Y, Hatake K. Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma. *Clin Cancer Res.* 15:2523-2530, 2009

33. Tanaka Y, Ikeda T, Kishi Y, Masuda S, Shibata H, Takeuchi K, Komura M, Iwanaka T, Muramatsu SI, Kondo Y, Takahashi K, Yamanaka S, Hanazono Y. ERas Is Expressed In Primate Embryonic Stem Cells But Not Related to Tumorigenesis. *Cell Transplant.* 2009
34. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H. KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer. *Clin Cancer Res.* 15:3143-3149, 2009
35. Mishima Y, Sugimura N, Matsumoto-Mishima Y, Terui Y, Takeuchi K, Asai S, Ennishi D, Asai H, Yokoyama M, Kojima K, Hatake K. An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy. *Clin Cancer Res.* 2009
36. Kiryu S, Takeuchi K, Shibahara J, Uozaki H, Fukayama M, Tanaka H, Maeda E, Akahane M, Ohtomo K. Epstein-Barr virus-positive inflammatory pseudotumour and inflammatory pseudotumour-like follicular dendritic cell tumour. *Br J Radiol.* 82:e67-71, 2009
37. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, Niwa A, Chen Y, Nakazaki K, Nomoto J, Asakura Y, Muto S, Tamura A, Iio M, Akatsuka Y, Hayashi Y, Mori H, Igarashi T, Kurokawa M, Chiba S, Mori S, Ishikawa Y, Okamoto K, Tobinai K, Nakagama H, Nakahata T, Yoshino T, Kobayashi Y, Ogawa S. Frequent inactivation of A20 in B-cell lymphomas. *Nature* 2009
38. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K, Soda M, Choi YL, Mano H, Ishikawa Y. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. *Mod Pathol.* 22:508-515, 2009
39. Imai H, Sugimoto K, Isobe Y, Sasaki M, Yasuda H, Takeuchi K, Nakamura S, Kojima Y, Tomomatsu J, Oshimi K. Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma. *Int J Hematol.* 89(5):673-8, 2009

H. 知的財産権の出願・登録状況
該当せず。

III. 研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
照井康仁	副作用対策におけるチーム医療の意義	弦間昭彦編集	分子標的治療薬の副作用のマネジメント	南江堂	東京	2011	15-22
照井康仁	CHAPTER6 悪性リンパ腫 —悪性リンパ腫化学療法選択の原則—	監修 島清彦	外来癌化学療法クリニカルパス実例集	メディカルレビュー社	東京	2011	180-184
照井康仁	CHAPTER7 白血病 —白血病化学療法選択の原則—	監修 島清彦	外来癌化学療法クリニカルパス実例集	メディカルレビュー社	東京	2011	204-205
照井康仁	CHAPTER8 多発性骨髄腫 —多発性骨髄腫化学療法選択の原則—	監修 島清彦	外来癌化学療法クリニカルパス実例集	メディカルレビュー社	東京	2011	221-222
湯浅健、羽刈友則	膀胱癌・病因新しい診断と治療のABC 腎癌・膀胱癌.	編集: 木原和徳		最新医学社	東京	2011	pp.143-152.
湯浅健、羽刈友則	腎がん・尿路がん・膀胱がん がん化学療法の進歩.	編集: 江口研二		医薬ジャーナル社	大阪	2011	pp.116-124.
湯浅健	最新化学療法レジメン 泌尿器がん			メジカルビュー社		2011	
三嶋雄二	あなたのがんに効く薬が分かる時代に	高橋伸児/ 奥村美穂	がんを薬で治す	朝日新聞出版	東京	2011	3-5
石川雄一	細気管支肺胞上皮癌とは、どのような癌ですか? 3. 肺癌の病理と分類	弦間昭彦(編著)	肺癌診療Q&A	中外医学社	東京	2011	24-25

石川雄一	ALK 融合遺伝子肺癌にはどのような臨床病理学的特徴がありますか？ 3. 肺癌の病理と分類	弦間昭彦(編著)	肺癌診療 Q & A	中外医学社	東京	2011	24-25
石川雄一、野口雅之	現在の組織分類には、どのような問題点がありますか？ 3. 肺癌の病理と分類	弦間昭彦(編著)	肺癌診療 Q & A	中外医学社	東京	2011	24-25
小野宏、石川雄一	3. 肺疾患の概要と鑑別診断。小細胞癌	青笹克之、松原修(編)	癌診療指針のための病理診断プラクティス 肺癌	中山書店	東京	2011	140-148
佐藤征二郎、石川雄一	7. 実際の症例。症例 2, EGFR 変異肺腺癌	青笹克之、松原修(編)	癌診療指針のための病理診断プラクティス 肺癌	中山書店	東京	2011	316-320
齋藤雄一、石川雄一	7. 実際の症例。症例 4, 肺線維症に伴う肺癌	青笹克之、松原修(編)	癌診療指針のための病理診断プラクティス 肺癌	中山書店	東京	2011	326-331

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Mishima Y, Kuniyoshi R, Taniyama A, Yokoyama M, Sakajiri S, Takeuchi K, Watanabe C, Takahashi S, Ito Y, Hatake K.	Identification of CD20 C-Terminal Deletion Mutations Associated With Loss of CD20 Expression in Non-Hodgkin's Lymphoma.	Clin Cancer Res	15 (7)	2523-2530	2009
Mishima Y, Sugimura N, Matsumoto-Mishima Y, Terui Y, Takeuchi K, Asai S, Ennishi D, Asai H, Yokoyama M, Kojima K, Hatake K.	An imaging-based rapid evaluation method for complement-dependent cytotoxicity.	Clin Cancer Res	15(10)	3624-3632	2009
Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, Miyamoto K, Kikuchi A, Hyo R, Yakushijin Y, Masaki Y, Fujii S, Hayashi T, Ishigatsubo Y, Miura I.	Clinicopathological features of lymphoma/ leukemia patients carrying both BCL2 and MYC translocations.	Haematologi ca.	94(7)	935-43.	2009
Tomita N, Takeuchi K, Hyo R, Hashimoto C, Takemura S, Taguchi J, Fujita H, Fujisawa S, Ogawa K, Motomura S, Ishigatsubo Y.	Diffuse Large B Cell Lymphoma without Immunoglobulin Light Chain Restriction by Flow Cytometry.	Acta Haematol.	121	196-201	2009
Tanaka Y, Ikeda T, Kishi Y, Masuda S, Shibata H, Takeuchi K, Komura M, Iwanaka T, Muramatsu SI, Kondo Y, Takahashi K, Yamanaka S, Hanazono Y.	ERas Is Expressed In Primate Embryonic Stem Cells But Not Related to Tumorigenesis.	Cell Transplant.			2009

Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H.	KIF5B-ALK, a Novel Fusion Oncokinin Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer.	Clin Cancer Res.	15	3143-3149	2009
Mishima Y, Sugimura N, Matsumoto-Mishima Y, Terui Y, Takeuchi K, Asai S, Ennishi D, Asai H, Yokoyama M, Kojima K, Hatake K.	An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy.	Clin Cancer Res.			2009
Kiryu S, Takeuchi K, Shibahara J, Uozaki H, Fukayama M, Tanaka H, Maeda E, Akahane M, Ohtomo K.	Epstein-Barr virus-positive inflammatory pseudotumour and inflammatory pseudotumour-like follicular dendritic cell tumour.	Br J Radiol.	82	e67-71	2009
Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, Niwa A, Chen Y, Nakazaki K, Nomoto J, Asakura Y, Muto S, Tamura A, Iio M, Akatsuka Y, Hayashi Y, Mori H, Igarashi T, Kurokawa M, Chiba S, Mori S, Ishikawa Y, Okamoto K, Tobinai K, Nakagama H, Nakahata T, Yoshino T, Kobayashi Y, Ogawa S.	Frequent inactivation of A20 in B-cell lymphomas.	Nature.			2009

Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K, Soda M, Choi YL, Mano H, Ishikawa Y.	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	Mod Pathol.	22	508-515	2009
Imai H, Sugimoto K, Isobe Y, Sasaki M, Yasuda H, Takeuchi K, Nakamura S, Kojima Y, Tomomatsu J, Oshimi K.	Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma.	Int J Hematol.	89(5)	673-8	2009
Wang W, Yuasa T, Tsuchiya N, Ma Z, Maita S, Narita S, Kumazawa T, Inoue T, Tsuruta H, Horikawa Y, Saito M, Hu W, Ogawa O, Habuchi T.	The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression, and clinical significance.	Int J Cancer.	125	2836-43.	2009
Yuasa T, Sato K, Ashihara E, Takeuchi M, Maita S, Tsuchiya N, Habuchi T, Maekawa T, Kimura S.	Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.	Cancer Immunol Immunother . ; :	58	493-502.	2009
Yuasa T.	Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.	Int J Urol.	16	731-2	2009
Tsuchiya N, Narita S, Kumazawa T, Inoue T, Ma Z, Tsuruta H, Saito M, Horikawa Y, Yuasa T, Satoh S, Ogawa O, Habuchi T.	Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer.	Oncol Rep.	22	493-9.	2009
Kumazawa T, Tsuchiya N, Saito M, Inoue T,	Cystoprostatectomy as a treatment of prostate cancer	Urol Int.	83	141-5.	2009

Narita S, Horikawa Y, Yuasa T, Satoh S, Kato T, Nanjyo H, Habuchi T.	involving the bladder neck.				
Kodaira M, Takahashi S, Takeuchi K, Yuasa T, Saotome T, Yonese J, Fukui I, Hatake K.	Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma in Japanese patients.	Ann Oncol.	21	1563-5.	2010
Ma Z, Tsuchiya N, Yuasa T, Huang M, Obara T, Narita S, Horikawa Y, Tsuruta H, Saito M, Satoh S, Ogawa O, Habuchi T.	Clinical Significance of Polymorphism and Expression of Chromogranin A and Endothelin-1 in Prostate Cancer.	J Urol.	184	1182-8.	2010
Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T.	Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.	Urology	75	1131-7.	2010
Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H.	A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety.	Jpn J Clin Oncol.	40	194-202.	2010
Tomita Y, Shinohara N, Yuasa T, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Uemura H, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H.	Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma.	Jpn J Clin Oncol.	40	1166-72.	2010
Matsusaka S(1), Chin K, Ogura M, Suenaga M, Shinozaki E, <u>Mishima Y</u> (以下 3 名省略)	Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer.	Cancer Sci	101(4)	1067-1071	2010

Takaba J, <u>Mishima Y</u> , Hatake K, Kasahara T.	Role of bone marrow-derived monocytes/macrophages in the repair of mucosal damage caused by irradiation and/or anticancer drugs in colitis model.	Mediators Inflamm.	2010	634145	2010
Akiyoshi T, Oya M, Fujimoto Y, Kuroyanagi H, Ueno M, Yamaguchi T, Takahashi S, Hatake K, Katori M, Yamamoto N, Muto T.	Complete resection after imatinib treatment of a gastrointestinal stromal tumor of the ileum with peritoneal metastases: report of a case.	Surg Today	40(3)	272-6	2010
Ogura M, Tobinai K, Hatake K, Uchida T, Kasai M, Oyama T, Suzuki T, Kobayashi Y, Watanabe T, Azuma T, Mori M, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Ono C, Ohata J.	Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy.	Cancer Sci.	101(8)	1840-5	2010
Mitsuhashi J, Hosoyama H, Tsukahara S, Katayama K, Noguchi K, Ito Y, Hatake K, Aiba K, Takahashi S, Sugimoto Y.	In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate.	J Gene Med.	12(7)	596-603	2010
Kodaira M, Takahashi S, Takeuchi K, Yuasa T, Saotome T, Yonese J, Fukui I, Hatake K.	Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.	Ann Oncol.	21(7)	1563-5	2010
Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T, Urade M.	Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons.	J Bone Miner Metab.	28(4)	365-83	2010

Osako T, Horii R, Matsuura M, Domoto K, Ide Y, Miyagi Y, Takahashi S, Ito Y, Iwase T, Akiyama F.	High-grade breast cancers include both highly sensitive and highly resistant subsets to cytotoxic chemotherapy.	J Cancer Res Clin Oncol.	136(9)	1431-8	2010
Osako T, Horii R, Matsuura M, Ogiya A, Domoto K, Miyagi Y, Takahashi S, Ito Y, Iwase T, Akiyama F.	Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.	J Cancer Res Clin Oncol.	136(2)	233-41	2010
Migita T, Narita T, Asaka R, Miyagi E, Nagano H, Nomura K, Matsuura M, Satoh Y, Okumura S, Nakagawa K, Seimiya H, <u>Ishikawa Y.</u>	Role of insulin-like growth factor binding proteins 2 in lung cancer: IGF independent anti-apoptotic effect via caspase-3	Am J Pathol	176	1756-66	2010
Hiramatsu M, Ninomiya H, Inamura K, Nomura K, Takeuchi K, Satoh Y, Okumura S, Nakagawa K, Yamori T, Matsuura M, Morikawa T, <u>Ishikawa Y.</u>	Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.	Lung Cancer	70	94-102	2010
Inamura K, Ninomiya H, <u>Ishikawa Y.</u> , Matsubara O.	Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?	Arch Pathol Lab Med.	134(1)	66-72	2010
Satoh Y, <u>Ishikawa Y.</u>	Primary pulmonary meningioma: Ten-year follow-up findings for a multiple case, implying a benign biological nature.	J Thorac Cardiovasc Surg.	139(3)	39-40	2010
Hoshi R, Furuta N, Horai T, <u>Ishikawa Y.</u> , Miyata S, Satoh Y.	Discriminant model for cytologic distinction of large cell neuroendocrine carcinoma from small cell carcinoma of the lung.	J Thorac Oncol.	(4); 5	472-8	2010
Hoshi R, Furuta N, Horai T, Takeuchi K, <u>Ishikawa Y.</u> , Satoh Y.	Implications for differential diagnosis of lung cancer-associated lymphadenopathy in lymphoepithelioid cell	Acta Cytol.	54(2)	197-201	2010

	lymphoma (Lennert's lymphoma) arising simultaneously with lung cancer: a case report.				
Inamura K, <u>Ishikawa Y.</u>	Lung cancer progression and metastasis from the prognostic point of view.	Clin Exp Metastasis.	27	389-97	2010
Sakao Y, Okumura S, Mun M, Uehara H, <u>Ishikawa Y.</u> , Nakagawa K.	Prognostic heterogeneity in multilevel N2 non-small cell lung cancer patients: importance of lymphadenopathy and occult intrapulmonary metastases.	Ann Thorac Surg.	89(4)	1060-3	2010
Okada A, Shimmyo T, Hashimoto T, Kobayashi Y, Miyagi Y, <u>Ishikawa Y.</u> , Nakagawa K, Hayashi J, Tsuchiya E.	Predictive advantage of a cell type classification for pulmonary adenocarcinoma coupled with data for p53, K-ras and EGFR alterations.	Cancer Sci.	101(7)	1745-53	2010
Mochizuki T, Okumura S, Ishii G, <u>Ishikawa Y.</u> , Hayashi R, Kawabata K, Yoshida J.	Surgical resection for oral tongue cancer pulmonary metastases.	Interact Cardiovasc Thorac Surg.	11(1)	56-9	2010
Ohba T, Motoi N, Kimura Y, Okumura S, Kawabata K, Yoshizawa Y, Inase N, <u>Ishikawa Y.</u>	Cytokeratin expression profiling is useful for distinguishing between primary squamous cell carcinoma of the lung and pulmonary metastases from tongue cancer.	Pathol Int.	60(8)	575-80	2010
Dan S, Okamura M, Seki M, Yamazaki K, Sugita H, Okui M, Mukai Y, Nishimura H, Asaka R, Nomura K, <u>Ishikawa Y.</u> , Yamori T.	Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.	Cancer Res.	70(12)	4982-94	2010
Uehara H, Sakao Y, Mun M, Nakagawa K, Nishio M, <u>Ishikawa Y.</u> , Okumura S.	Prognostic value and significance of subcarinal and superior mediastinal lymph node metastasis in lower lobe tumours.	Eur J Cardiothorac Surg.	38	498-502	2010
Takeuchi S, Takahashi A, Motoi N, Yoshimoto S, Tajima T, Yamakoshi K, Hirao A, Yanagi S, Fukami K, <u>Ishikawa Y.</u> , Sone S, Hara E, Ohtani	Intrinsic cooperation between p16INK4a and p21Waf1/Cip1 in the onset of cellular senescence and tumor suppression in vivo.	Cancer Res.	70(22)	9381-90	2010

N.					
Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, <u>Ishikawa Y</u> , Kimura H, Mitsudomi T, Tanio Y, Mano H.	ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.	N Engl J Med.	363(18)	1734-9	2010
Hyo R, Tomita N, Takeuchi K, Aoshima T, Fujita A, Kuwabara H, Hashimoto C, Takemura S, Taguchi J, Sakai R, Fujita H, Fujisawa S, Ogawa K, Motomura S, Suzuki R, Ishigatsubo Y.	The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.	Hematol Oncol.	28(1)	27-32	2010
Ennishi D, Yokoyama M, Terui Y, Asai H, Sakajiri S, Mishima Y, Takahashi S, Komatsu H, Ikeda K, Takeuchi K, Tanimoto M, Hatake K.	Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.	Ann Oncol.	20	526-533	2010
Nakajima T, Kimura H, Takeuchi K, Soda M, Mano H, Yasufuku K, Iizasa T.	Treatment of Lung Cancer with an ALK Inhibitor After EML4-ALK Fusion Gene Detection Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration.	J Thorac Oncol.	5	2041-2043	2010
Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, Ishikawa Y, Kimura H,	EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.	N Engl J Med.	363	1734-1739	2010

Mitsudomi T, Tanio Y, Mano H.					
Nishimori H, Takahashi S, Kiura K, Ennishi D, Kobayashi T, Sano K, Shinozaki E, Yokoyama M, Mishima Y, Terui Y, Chin K, Mizunuma N, Ito Y, Nishimura S, Takeuchi K, Ishikawa Y, Oguchi M, Tanimoto M, Hatake K.	Cancer of unknown primary site:a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan.	Acta Med Okayama.	64	285-291	2010
Jokoji R, Yamasaki T, Minami S, Komuta K, Sakamaki Y, Takeuchi K, Tsujimoto M.	Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma.	J Clin Pathol.	63	1066-1070	2010
Sakairi Y, Nakajima T, Yasufuku K, Ikebe D, Kageyama H, Soda M, Takeuchi K, Itami M, Iizasa T, Yoshino I, Mano H, Kimura H.	EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration.	Clin Cancer Res	16	4938-4945	2010
Takeuchi K, Yokoyama M, Ishizawa S, Terui Y, Nomura K, Marutsuka K, Nunomura M, Fukushima N, Yagyuu T, Nakamine H, Akiyama F, Hoshi K, Matsue K, Hatake K, Oshimi K.	Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation.	Blood	116	5631-5637	2010
Asai H, Yokoyama M, Terui Y, Ennishi D, Takeuchi K, Hatake K.	Is statin use really associated with efficacy of rituximab?	J Clin Oncol.	28	e424-425; author reply e427-428	2010

Hoshi R, Furuta N, Horai T, Takeuchi K, Ishikawa Y, Satoh Y.	Implications for differential diagnosis of lung cancer-associated lymphadenopathy in lymphoepithelioid cell lymphoma (Lennert's lymphoma) arising simultaneously with lung cancer: a case report.	Acta Cytol.	54	197-201	2010
Ichinohasama R, Oji Y, Yokoyama H, Takeuchi K, Fujiwara T, Ishizawa K, Taniguchi O, Tsuboi A, Oka Y, Sugiyama H.	Sensitive immunohistochemical detection of WT1 protein in tumors with anti-WT1 antibody against WT1 235 peptide.	Cancer Sci	101	1089-1092	2010
Tsuji H, Tamura M, Yokoyama M, Takeuchi K, Mimura T.	Ocular involvement by epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: a new disease entity in the world health organization classification.	Arch Ophthalmol.	128	258-259	2010
Mano H, Takeuchi K.	EML4-ALK fusion in lung.	Am J Pathol.	176	1552-1553 ; author reply 1553-1554	2010
Watanabe R, Tomita N, Takeuchi K, Sakata S, Tateishi U, Tanaka M, Fujita H, Inayama Y, Ishigatsubo Y.	SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma.	Leuk Lymphoma.	51	279-283	2010
Kodaira M, Takahashi S, Yamada S, Ueda K, Mishima Y, Takeuchi K, Yamamoto N, Ishikawa Y, Yokoyama M, Saotome T, Terui Y, Hatake K.	Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy.	Ann Oncol.	21	1163-1167	2010

Ennishi D, Asai H, Maeda Y, Shinagawa K, Ikeda K, Yokoyama M, Terui Y, Takeuchi K, Yoshino T, Matsuo K, Hatake K, Tanimoto M.	Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.	Ann Oncol.	21	1217-1221	2010
Yuasa T, Urakami S, Yamamoto S, Yonese J, Nakano K, Kodaira M, Takahashi S, Hatake K, Inamura K, Ishikawa Y, Fukui I.	Tumor Size is a Potential Predictor of the Response to Tyrosine Kinase Inhibitors in Renal Cell Cancer.	Urology	77:	831-5.	2011
Matsusaka S, Mishima Y, Suenaga M, Terui Y, Kuniyoshi R, Mizunuma N, Hatake K.	Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.	Cancer	117	4026-32	2011
Matsusaka S, Suenaga M, Mishima Y, Kuniyoshi R, Takagi K, Terui Y, Mizunuma N, <u>Hatake K.</u>	Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer.	Cancer Sci. ;,	102(6)	1188-92	2011
Matsusaka S, Suenaga M, Mishima Y, Takagi K, Terui Y, Mizunuma N, Hatake K.	Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.	Cancer Chemother Pharmacol.	68(3)	763-8	2011
Dana Rathkopf, Glenn Liu, Michael A Carducci, Mario A Eisenberger, Aseem Anand, Michael J Morris, Susan F Slovin, Yasutsuna Sasaki, Shunji Takahashi, Seiichiro Ozono, Nga Kit Eliza Fung, Shinta Cheng, Jinping Gan, Marco Gottardis, Mary T. Obermeier, Jyotsna Reddy, Steven Zhang, Blisse J. Vakkalagadda, George Wilding, and Howard I. Scher.	Phase I Dose-Escalation Studies of BMS-641988 in Patients with Castration-Resistant Prostate Cancer.	Clin Cancer Res	17(4)	880-7.	2011

Yoshinori Ito, Koichi Nagasaki, Yoshio Miki, Takuji Iwase, Futoshi Akiyama, Masaaki Matsuura, Rie Horii, Masujiro Makita, Nahomi Tokudome, Masaru Ushijima, Masataka Yoshimoto, Shunji Takahashi, Tetsuo Noda and Kiyohiko Hatake.	Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer.	Cancer Science	102(1)	130-6	2011
Yuasa T, Urakami S, Yamamoto S, Yonese J, Saito K, Takahashi S, Hatake K, Fukui I.	Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis.	Clin Exp Metastasis	28(4)	405-11.	2011
Tokudome N, Ito Y, Takahashi S, Kobayashi K, Taira S, Tsutsumi C, Oto M, Oba M, Inoue K, Kuwayama A, Masumura K, Nakayama Y, Watanabe C, Hatake K.	Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients.	Breast Cancer.	18(3)	195-202.	2011
Yuasa T, Takahashi S, Hatake K, Yonese J, Fukui	Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.	Cancer Sci.	102(11)	1949-57.	2011
Urakami S, Yonese J, Yamamoto S, Yuasa T, Kitsukawa S, Numao N, Kubo Y, Ito M, Sukegawa G, Yasuda Y, Ishikawa Y, Fukui I.	Outcome of Antegrade Radical Prostatectomy with Intended Wide Resection in Prostate Cancer Patients with a Preoperative Serum PSA Level >100 ng/ml.	Urol Int.	87	175-81.	2011
Ito M, Saito K, Yasuda Y, Sukegawa G, Kubo Y, Numao N, Kitsukawa S, Urakami S, Yuasa T, Yamamoto S, Yonese J, Fukui I.	Prognostic Impact of C-reactive Protein for Determining Overall Survival of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel.	Urology.	78	1131-5.	2011
Narita S, Tsuchiya N, Yuasa T, Maita S, Obara T, Numakura K, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S,	Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel,	Int J Clin Oncol		in press	2011

Habuchi T.	estramustine phosphate and carboplatin for castration-resistant prostate cancer.				
Saito M, Tsuchiya N, Maita S, Numakura K, Obara T, Tsuruta H, Kumazawa T, Inoue T, Narita S, Horikawa Y, Yuasa T, Satoh S, Habuchi T.	What Is the Most Preferred Wound Site for Laparoscopic Donor Nephrectomy?: A Questionnaire Assessment.	J Laparoendosc Adv Surg Tech A	21	511-5.	2011
Yuasa T, Fujii Y, Takahashi S, Fukui I, Yonese J.	Molecular targeted therapies for patients with metastatic renal cell cancer.	Translational Med		in press	
Numakura K, Tsuchiya N, Yuasa T, Saito M, Obara T, Tsuruta H, Narita S, Horikawa Y, Satoh S, Habuchi T.	A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib.	Int J Clin Oncol	16	577-80.	2011
Y Mishima, Y Terui, K Takeuchi, Y Matsumoto-Mishima, S Matsusaka, R Utsubo-Kuniyoshi, and K Hatakel	The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations	Blood Cancer J	1(4)	15-18	2011
Ishikawa N, Nakamura K, Izumiyama-Shimomura N, Aida J, Ishii A, Goto M, Ishikawa Y, Asaka R, Matsuura M, Hatamochi A, Kuroiwa M, Takubo K.	Accelerated in vivo epidermal telomere loss in Werner syndrome	Aging (Albany NY).	3(4)	417-29	2011
Sakao Y, Okumura S, Mun M-y, Uehara H, Ishikawa Y, Nakagawa K.	The impact of superior mediastinal lymph node metastases on prognosis in non-small cell lung cancer located in the right middle lobe.	J Thorac Oncol	6(3)	494-9	2011
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC,	International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.	J Thorac Oncol.	6(2)	244-85	2011

Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D.					
Kudo K, Ohyanagi F, Horiike A, Miyauchi E, Yanagitani N, Hoshi R, Satoh Y, Motoi N, Hamanaka W, Ishikawa Y, Mun M, Sakao Y, Okumura S, Nakagawa K, Horai T, Nishio M.	Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations.	Lung Cancer	74	401-4	2011
Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y.	RET, ROS1 and ALK fusions in lung cancer.	Nat Med.			on line
Sugawara E, Togashi Y, Kuroda N, Sakata S, Hatano S, Asaka R, Yuasa T, Yonese J, Kitagawa M, Mano H, Ishikawa Y, Takeuchi K.	Identification of anaplastic lymphoma kinase fusions in renal cancer: Large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.	Cancer			on line
Kijima T, Takeuchi K, Tetsumoto S, Shimada K, Takahashi R, Hirata H, Nagatomo I, Hoshino S, Takeda Y, Kida H, Goya S, Tachibana I, Kawase I.	Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.	Cancer Sci	102	1602-1604	2011
Takeuchi K, Soda M, Togashi Y, Sugawara E, Hatano S, Asaka R, Okumura S, Nakagawa K, Mano H, Ishikawa Y.	Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification.	Clin Cancer Res.	17	3341-3348	2011
Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, Asaka R, Nakajima T, Mano H, Takeuchi K.	KLC1-ALK: A novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only.	PLoS One	7	e31323	2012
Numao N, Kawakami S, Sakura M, Yoshida S, Koga F, Saito K, Masuda H, Fujii Y, Yamamoto S, Yonese J, Ishikawa Y.	Characteristics and clinical significance of prostate cancers missed by initial transrectal 12-core biopsy.	BJU Int.	09(5):	665-71.	2012